Latest European Markets News

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.

Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

European Lithium has sold 0.5 million shares of Critical Metals Corp for US$1.625 million, underscoring the substantial value of its remaining CRML stake, now valued at approximately US$205 million.

Argent BioPharma has begun supplying its EU-GMP cannabinoid API for drug-resistant epilepsy treatment at University Medical Centre Ljubljana, marking a key clinical and regulatory milestone in Europe.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Sprintex secures a key deposit from Mest Water to develop new compressors for mobile manure processing systems, leveraging a Dutch government subsidy aimed at thousands of small farms.

Unibail-Rodamco-Westfield will voluntarily delist from the ASX by late August 2025, citing low liquidity and rising compliance costs. Australian investors holding CHESS Depositary Interests face key decisions on how to manage their holdings.

Collins Foods reported a record $1.52 billion revenue for FY25 with flat EBITDA despite tough market conditions, while signaling optimism for low to mid-teens NPAT growth in FY26.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.